Tumors in Italy: an overview

The data of Istituto Superiore della Sanità indicates that the national average of patients who undergo a colorectal cancer screening is of about 42,6% (60% in the North, 20% in the South).

The data are not surprising: the current and available screening programs for the diagnosis are invasive and expensive exams that discourage the patients.

Source: The European House – Ambrosetti, based on data produced by Istituto Superiore della Sanità, 2019.

CANCER INCIDENCE

Breast cancer
14%
Colorectal cancer
13%
Lung cancer
11%
Prostate cancer
10%

Skin cancers are not included.

CANCER MORTALITY

Lung cancer
20%
Colorectal cancer
11%
Breast cancer
8%
Prostate cancer
6%

Statistics produced by Associazione italiana registri tumori (AIRTUM)

FOCUS ON COLORECTAL CANCER

Statistics related to the colorectal cancer in the male (on the left) and female population (on the right), (2000-2015).
Source: The European House – Ambrosetti based on data produced by Istituto Superiore della Sanità, 2016.

Despite the increase in the standardised incidence rate, screening activities allow the decrease of the standardised mortality rate.

EARLY DIAGNOSIS OF COLORECTAL CANCER

Fecal occult blood test

(first level screening test)

→ high number of false-positive results
→ very high cost-benefit ratio

Flexible sigmoidoscopy/colonscopy

(second level screening test)

→ expensive and invasive exam

MISTRAL: THE PERFECT SOLUTION FOR EARLY DIAGNOSIS

Mistral is the best solution for the early diagnosis of the colorectal cancer because it allows the sampling and testing of the patients’ breath on a large scale: it is not invasive, yet rapid, inexpensive and portable.

Mistral is useful for both the patient and the healthcare system because it helps reduce costs and shorten waiting lists.

This site uses cookies to improve the browsing experience of users and to gather information on the use of the site. You can know the details by consulting our cookie policy.